Healthcare Firm Uncovers AI Healthcare Growth Opportunity

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for the quote from the Clive Maund article published on May 21, 2025

1. For the quoted article (published on May 21, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be  only be construed as a recommendation or solicitation to buy and sell securities.

Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) digital healthcare platform and marketplace Rocket Doctor was among the 15 companies chosen to be part of this year's Heal.LA, a program by the nonprofit organization Larta Institute that supports and promotes innovative bioscience and healthcare startups working to close care gaps in underserved communities in Los Angeles, Calif., according to a news release.

‏"Rocket Doctor brings exactly the kind of bold, mission-driven innovation that Heal.LA was built to support," Larta Institute Founder and Chief Executive Officer (CEO) said in the release. "Their physician-led approach and smart use of technology make care more immediate, more human and more accessible, especially for patients who are often overlooked."

Sir Tony Blair, former prime minister of the United Kingdom, said recently that "fears over artificial intelligence should be outweighed by the 'absolutely transformative' impact it could have on public services [such as healthcare] by saving time and cutting costs," Lucy Bannerman of The Times reported. "You should have AI nurses, AI doctors."

Rocket Doctor's platform allows healthcare providers to build and manage their own virtual or hybrid practices and to deliver care remotely using artificial intelligence (AI)-enabled tools and connected diagnostic devices.‏

As part of the Bioscience and Healthcare Accelerator cohort, Rocket Doctor will gain strategic mentorship, regulatory and reimbursement support, and access to Larta's Ecosystem Action Network (EAN), a group of healthcare leaders, funders and potential partners. With these resources, Rocket Doctor can expand its service reach and connect with new patient populations, particularly in greater-need communities.

‏"Joining the Heal.LA accelerator gives us the opportunity to build new partnerships, reach more patients and accelerate our growth in the U.S.," Rocket Doctor CEO and Founder Dr. William Cherniak said in the release. "Through this collaboration, we expect to drive more patient bookings by expanding our visibility and tapping into local networks that serve those most in need of care."

Reimagining Today's Healthcare

Rocket Doctor's parent company Treatment.com AI Inc., based in British Columbia, is on a mission to transform healthcare globally into a system based on trusted medical intelligence. To this end, it leverages AI, machine learning and best clinical practices with a goal  to improve healthcare by delivering precise medical insights, assisting various types of providers and students, and eradicating inefficiencies.

There are three key components to Treatment.com's digital healthcare offerings, according to its Investor Presentation. One is its proprietary, accurate medical knowledge base, the Global Library of Medicine (GLM) digital platform, developed using internal algorithms and the input of hundreds of healthcare professionals around the world. Consistently updating and improving, the GLM contains about 10,000+ expert medical reviews, diagnoses for 1,000-plus diseases and 15,000-plus symptoms. It suggests appropriate lab tests and imaging, treatment options and billing codes. The GLM has been designed to be integrated through APIs, in a plug-and-play fashion, into a variety of platforms or organizations.

The GLM is designed to help healthcare professionals (physicians, nurses and/or pharmacists) lessen their administrative burden. It creates more time for effective face-to-face patient appointments and aims to make the quality of patient support more consistent.

The second is AI-powered triage, as an example effected through Treatment.com's emerging AI-Voice Assistant. This combines conversational AI and voice technology to improve patient interactions through various processes like onboarding. Treatment also envisages the AI-Voice Assistant helping expand access to care support, post discharge and mental health.

The third is Rocket Doctor's virtual care tools described as "Shopify for physicians," which allow providers to deliver smarter, faster and safer care, remotely or not, with a focus on underserved communities across North America.

The Catalyst: Robust Market Growth Ahead

AI in healthcare can enhance the accuracy and efficiency of diagnosis, treatment and patient care. AI algorithms can analyze massive amounts of medical data, identify patterns and make predictions that guide clinical decision-making, ultimately for improved patient outcomes. Industry experts made these assertions during a panel discussion on how AI and data integration can lead to better healthcare, at the recent 2025 Healthcare Information and Management Systems Society (HIMSS) global conference, as reported in a June 2 article posted by Anna Hogrebe with Philips.

A recent survey of healthcare professionals revealed that 82% of respondents believe AI and predictive analytics can save lives by facilitating earlier interventions. Seventy-five percent said they agree that digital health technologies, including AI and predictive analytics, will reduce hospital admissions in the future. Survey responses were collected between December 2024 and April 2025 from 16,000 patients and 2,000 clinicians from 16 countries and recorded in Philips' Future Health Index 2025.

When it comes to personalized medicine, the HIMSS panelists noted, AI can take it to another level. Specifically, AI algorithms can pinpoint the most effective treatment options for a specific person by analyzing their genetic profile, medical history and lifestyle. AI-powered chatbots can give patients personalized health advice and support, thereby potentially improving their well-being and level of involvement in their own care.

Along with patient care, AI also can transform clinical trials, drug discovery and administrative tasks, Precedence Research indicated. The use of AI technology in everything from diagnostic tools to personalized treatments is helping healthcare professionals make better informed decisions quicker.

Sir Tony Blair, former prime minister of the United Kingdom, said recently that "fears over artificial intelligence should be outweighed by the 'absolutely transformative' impact it could have on public services [such as healthcare] by saving time and cutting costs," Lucy Bannerman of The Times reported on June 2. "You should have AI nurses, AI doctors."

The global AI in healthcare market is forecasted to expand at a 38.6% compound annual growth rate between 2025 and 2030, according to Research and Markets. During this period, the market is projected to reach US$111 billion (US$111B) from US$22B in value. Growth drivers are increasing AI integration, advancements in human-aware AI systems and investments from the public and private sectors.

Other contributing factors, according to Precedence, include the growing demand for personalized medicine, the reduced costs and the greater efficiency that result, and improved patient outcomes. On the flip side, hindrances to market expansion include concerns about data privacy and security as well as regulatory and ethical issues.

Stock Looks Ready to Break Out

*In a May 21 report, Technical Analyst Clive Maund highlighted Treatment.com's technologies and both Treatment and Rocket Doctor's relationships with major medical organizations in the U.S. and Canada.

"Treatment.com AI is positioning to be a major player in the AI transformation of healthcare," Maund wrote. "This being so, I believe the outlook for the company and its stock is very bright indeed."

Treatment.com's charts show that a large base pattern has been forming since late 2022. While this was happening, the 200-day moving average dropped to a level near the price. This generally occurs before a new bull market.

"This [base] pattern now looks mature," the analyst added. "Given the extraordinarily bright prospects for the company, the time is believed to be at hand for the stock to advance, to break out above the key resistance."

As such, it is a good time to buy or add to positions, Maund pointed out. He noted the first target range for an advance is CA$1.08–1.12, the second, CA$4, with much higher targets possible later. In comparison, Treatment.com's share price was CA$0.38 at the end of trading on June 4.

Ownership and Share Structure

Insider and institutional ownership of Treatment.com AI totals 5.10%, the company said. Co-founder and Chief Medical Officer Dr. Kevin Peterson is the majority shareholder with 5.09%. Institutional investors are Palos Management Inc. and StoneCastle Investment Management  Inc., according to latest information from Refinitiv. The rest is in retail.

As of June 5, 2025, the healthcare tech company has 75.5 million outstanding shares and 57.9 million free float traded shares. Its market cap is CA$28.31 million. Its 52-week range is CA$0.34–1.11 per share.